#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucopolysaccharidosis II Biliary neoplasm Short-bowel syndrome Depression Candida infection Gastric cancer Superficial vein thrombosis Transferrin decreased Acute leukaemia Chronic kidney disease Adenocarcinoma gastric Haemophilia B with anti factor IX Polycystic liver disease Hyperinsulinaemic hypoglycaemia T-cell lymphoma More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma refractory – Treatment Glomerulonephritis membranous – Trials in Disease Congenital generalised lipodystrophy – Basic Information Mastocytosis – Diagnostics Atypical haemolytic uraemic syndrome Piriformis syndrome Lymphangioma Angiosarcoma non-metastatic – Life with Disease Breast angiosarcoma metastatic – Diagnostics Glomerulonephritis membranoproliferative – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vancomycin Citric Acid Monohydrate NERANDOMILAST FLUCLOXACILLIN SODIUM Rbl035.2 Pirtobrutinib Chlorpromazine Hydrochloride Bemarituzumab Pbf-999 Asundexian Volixibat Magnesium Sulfate Timolol Sar441566 Tamuzimod Acetate Ifinatamab Deruxtecan Tildrakizumab Hydrocortisone Fosfomycin Trometamol Simoctocog Alfa More therapies…

    Learn about Your Condition

    Cachexia Hepatitis B Pharyngeal cancer stage III Usher's syndrome Glycogen storage disorder Pancoast's tumour Burning mouth syndrome Cervix carcinoma recurrent Femur fracture Congenital pseudarthrosis Nephropathy Round cell liposarcoma Neonatal asphyxia Acute HIV infection Cancer pain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Metronomic Chemotherapy for Children and Teenagers with Relapsed or Refractory Wilms Tumor Using Vincristine, Irinotecan, Etoposide, Temozolomide, and Isotretinoin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Nephroblastoma
    Investigated Drugs:
    • Etoposide
    • Irinotecan
    • Isotretinoin
    France

  • Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Darolutamide
    • Degarelix
    • Goserelin
    Belgium France Ireland Spain

  • Study of Talazoparib and Enzalutamide combination treatment for patients with metastatic prostate cancer who previously received Abiraterone

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Enzalutamide
    • Talazoparib
    France Spain

  • Study of Amivantamab, Pembrolizumab, and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Amivantamab
    • Carboplatin
    • Pembrolizumab
    France Germany Poland Spain

  • Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

    Recruiting

    3 1
    Investigated Diseases:
    • Chondrosarcoma
    Investigated Drugs:
    • Ivosidenib
    Belgium Denmark France Germany Italy The Netherlands +1

  • Study on Dinutuximab Beta with Chemotherapy for Children and Teens with Newly Diagnosed High-Risk Neuroblastoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Cyclophosphamide
    Austria France Germany Italy The Netherlands Poland +1

  • Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Niraparib
    • Niraparib Tosilate Monohydrate
    Belgium France Italy Spain

  • Study on Mifamurtide with Chemotherapy for Patients with High-Risk Osteosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Cisplatin
    • Doxorubicin Hydrochloride
    • Etoposide
    France

  • Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Small intestine adenocarcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Fluorouracil
    • Irinotecan Hydrochloride Trihydrate
    France Italy

  • Study on the Safety and Tolerability of ODM-212 for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    • Odm-212
    Finland France Spain
Previous Page
1 … 8 9 10 11 12 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!